Evidence map›Paper›PMID 40871080›Full record

ReviewPharmaceutics2025

Nanocarriers in Ungual Drug Delivery.

Sheila Porto de Matos, Karen de Oliveira Araujo, Tainá Kreutz, Valdir Florêncio da Veiga Júnior, Helder Ferreira Teixeira, Letícia Scherer Koester

Abstract readReview
In one paragraph

Review in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sheila Porto de MatosPrograma de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul, Av. Ipiranga, 2752, Porto Alegre 90610-000, Brazil.ORCID 0000-0003-1546-5495
Karen de Oliveira AraujoPrograma de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul, Av. Ipiranga, 2752, Porto Alegre 90610-000, Brazil.ORCID 0009-0002-3289-5841
Tainá KreutzPrograma de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul, Av. Ipiranga, 2752, Porto Alegre 90610-000, Brazil.ORCID 0000-0002-1752-405X
Valdir Florêncio da Veiga JúniorPrograma de Pós-Graduação em Química, Instituto Militar de Engenharia, Praça General Tibúrcio, Urca, 80, Rio de Janeiro 22290-270, Brazil.ORCID 0000-0003-1365-7602
Helder Ferreira TeixeiraPrograma de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul, Av. Ipiranga, 2752, Porto Alegre 90610-000, Brazil.
Letícia Scherer KoesterPrograma de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul, Av. Ipiranga, 2752, Porto Alegre 90610-000, Brazil.ORCID 0000-0002-1043-5855

Funding

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior 001
6 · The paper itself

Abstract

Ungual disorders can impact quality of life, with onychomycosis and nail psoriasis being the most prevalent disorders among the general population. In humans, the main functions of the nail apparatus comprise protection against trauma, improvement of tactile sensations, and allowing precision gripping. In order to perform such functions, the nail plate has a hard structure formed by dead keratinized corneocytes tightly bound to each other, giving the nail plate a "barrier-like" character. Due to this property of the nail plate, drug delivery to the region is hindered, making the treatment of ungual disorders difficult, either by systemic or topical drug administration. Many strategies have been developed in the last few decades in an attempt to increase the bioavailability of drugs in the nail. Interest in the employment of nanostructured drug delivery systems aiming to increase the bioavailability of drugs in the nail plate upon topical administration has increased. Moreover, the association of the nanotechnological approaches with other methods may be a beneficial strategy when aiming to increase drug permeation through the nail barrier. In this sense, the present review has the intention of presenting the panorama of the current technological development of nanostructured systems designed for the local treatment of ungual disorders. Through this extensive literature review, it was possible to recognize, among the studies, a lack of standardization regarding the methodology of nail permeation assessment, which imposes an obstacle to comparison.

Indexed as

nail disordersnanostructured systemsonychomycosispsoriasisungual drug delivery

Identifiers

PMID40871080
PMCPMC12389257

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.